KBC Group
NVAX icon

KBC Group’s Novavax NVAX Stock Holding History

KBC Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39K Buy
4,746
+1,229
+35% +$11.1K ﹤0.01% 1730
2025
Q4 		$24K Hold
3,517
– – ﹤0.01% 1723
2025
Q3 		$30K Hold
3,517
– – ﹤0.01% 1721
2025
Q2 		$22K Sell
3,517
-4,437
-56% -$29.4K ﹤0.01% 1705
2025
Q1 		$51K Hold
7,954
– – ﹤0.01% 1786
2024
Q4 		$64K Buy
7,954
+3,917
+97% +$37.8K ﹤0.01% 1766
2024
Q3 		$51K Hold
4,037
– – ﹤0.01% 1701
2024
Q2 		$51K Buy
+4,037
New +$40.6K ﹤0.01% 1601
2023
Q4 		– Sell
-1,798
Closed -$13K – 1897
2023
Q3 		$13K Buy
+1,798
New +$14.4K ﹤0.01% 1910
2022
Q4 		– Sell
-736
Closed -$13K – 1544
2022
Q3 		$13K Hold
736
– – ﹤0.01% 1539
2022
Q2 		$38K Sell
736
-2,520
-77% -$131K ﹤0.01% 1467
2022
Q1 		$240K Hold
3,256
– – ﹤0.01% 998
2021
Q4 		$466K Sell
3,256
-2,436
-43% -$419K ﹤0.01% 890
2021
Q3 		$1.18M Sell
5,692
-5,692
-50% -$1.25M ﹤0.01% 738
2021
Q2 		$2.42M Buy
+11,384
New +$2.09M ﹤0.01% 741

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KBC Group's NVAX Position: Q1 2026 in Review

KBC Group increased its Novavax (NVAX) stake by 35% in Q1 2026, buying an estimated $11.1K and bringing the position to 4,746 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

KBC Group first reported a position in NVAX in Q2 2021 and has held it in 15 quarters since. The position peaked at $2.42M in Q2 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • KBC Group held 4,746 shares of Novavax worth $39K as of Q1 2026.
  • KBC Group bought 1,229 Novavax shares in Q1 2026, an estimated $11.1K.
  • Novavax made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1730 holding.
  • KBC Group first reported a position in Novavax in Q2 2021 and has held it in 15 quarters since.
  • KBC Group's Novavax position peaked at $2.42M in Q2 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.